TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01195740

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced Usual Care
Description: Belmont offers the Therapeutic Bridge Program, funded by the Pew Charitable Trusts, which helps adolescents make the transition from the hospital back to home, school and community behavioral health services. The program serves as a bridge between inpatient and outpatient care during the first 90 days after discharge, linking them to supportive services. Aftercare begins at the point of intake. Several discharge planning meetings are held with the adolescent and parents during the inpatient stay. The range of services are based on the patient and families' need, and may include meeting with school personnel , conducting home visits or making referrals to other community services agencies. The main objective is to secure outpatient mental health services for the patient. These services will be enhanced by the weekly research tracking, assessment and 24-hour crisis phone line which will call into a cell phone rotated among the licensed mental health professionals on the research team.
Study: NCT02615548

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: community-based exercise class
Description: This intervention will be held in a community centre, twice per week, for 36 weeks.The participants will have an educational session regarding importance of regular exercise.The class will consist of evidence-based exercises such as: sustained, high effort exercises, resistance exercises, and endurance training.Two trainers with specific for Parkinson Disease training will lead the class.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: self-directed physical activity
Description: Participants from this group will have an educational session regarding importance of regular exercises for Parkinson Disease and will be asked to stay as active as possible.Both groups will be asked to fill out physical activity diary.
Study: NCT01795521

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiotherapy (SBRT)
Description: A form of radiation therapy, where only the primary tumor is targeted and precise stereotactic tumor localization combined with techniques reducing breathing- induced target motion allowed small safety margins. These small volumes are treated with hypo-fractionated, escalated irradiation doses. It's now further developed in multiple clinical and technological aspects e.g. FDG-PET/CT based nodal staging, respiration correlated CT- imaging for target volume definition and image-guided treatment delivery.
Study: NCT04059913

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Roxadustat
Description: Roxadustat will be dosed orally per dose and schedule specified in the arm description.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Roxadustat
Description: Roxadustat will be dosed orally per dose and schedule specified in the arm description.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Roxadustat
Description: Roxadustat will be dosed orally per dose and schedule specified in the arm description.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Roxadustat
Description: Roxadustat will be dosed orally per dose and schedule specified in the arm description.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Roxadustat
Description: Roxadustat will be dosed orally per dose and schedule specified in the arm description.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Roxadustat
Description: Roxadustat will be dosed orally per dose and schedule specified in the arm description.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Roxadustat
Description: Roxadustat will be dosed orally per dose and schedule specified in the arm description.
Study: NCT02125318

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anagrelide CR
Description: Starting dose of 0.5 mg b.i.d. (1.0 mg/day) titrated at weekly intervals, on an individual basis, to achieve the lowest dose required to achieve and maintain a target platelet count of 150 - 400 x 10e9/L, tolerability permitting. The dose will be increased at weekly intervals in steps not exceeding 0.5 mg/day; the rate of dose titration may be reduced (i.e., up to once every 2 weeks) at the discretion of the Investigator.
Study: NCT00509821

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzastaurin 500 milligram (mg) Once Daily (QD)
Description: 1125 mg loading dose D(-)7 then 500 mg QD, oral, daily until disease progression, given with and without radiotherapy treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzastaurin 250 mg Twice Daily (BID)
Description: 1125 mg loading dose D(-)7 then 250 mg BID, oral, daily until disease progression, given with and without radiotherapy treatment.
Study: NCT03436043

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transmural Plastic stenting
Description: After metal stent removal in patients of disconnected pancreatic duct syndrome, transmural plastic- double pig tail stent will be placed into the residual necrotic cavity with the standard duodenoscope.
Study: NCT02622464

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: micro injection of SVF in vocal cords
Study: NCT03157492

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aural Rehabilitation Group
Description: Participants will complete sessions in their home or office via the internet. Sessions will include listening activities, informational counseling and communication strategies training. Three assessment appointments are required. The goal is to evaluate the benefit of training on performance with a cochlear implant.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Cognitive Training Group
Description: The Cognitive Training Group will receive six 90-minute sessions including training exercises (Ken-Ken, Sudoku, Crosswords, Word Search, Spot the Difference) to improve speed and accuracy. Three assessment sessions are also required.
Study: NCT04137302

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydrocortisone administration
Description: Hydrocortisone administration with collection of blood, urine and saliva samples before (1 week), during (5 days) and after (1 week) the 2 treatments

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydrocortisone administration
Description: Hydrocortisone administration with collection of blood, urine and saliva samples before (1 week), during (5 days) and after (1 week) the 2 treatments
Study: NCT03380598

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CLOSS
Description: Usual care plus using mobile application's to register weight and physical activity as well as for communication with the clinic. A web-based system enables health care professionals to follow the the patient's daily weight registration online.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Usual care. The child and parent(s) at regular visits to the nurse at the clinic
Study: NCT01520077

Intervention type: DRUG
Group type: OTHER
Intervention: vytorin
Description: Patient will take once per day by mouth Vytorin 10/40mg. Will take it for 24 weeks and then continue or discontinue treatment at that time and be monitored for 24 more weeks. Should there be no improvement by the initial 24 weeks then they will no longer be in the study.
Study: NCT00347737

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: teriparatide
Description: Teriparatide
Study: NCT00196378

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Synthetic Conjugated estrogens, B
Description: 1 (0.3mg) tablet daily

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 tablet daily
Study: NCT04479514

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Warm Baths or Showers
Description: Daily warm baths or showers

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Moisturizer
Description: moisturizers applied daily immediately after bathing

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPF 30 or Higher Suncreen
Description: Mineral based sunscreen of SPF 30 or higher applied on a daily basis on all sun exposed areas.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sun Protective Clothing
Description: Sun protective clothing worn when outdoors

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Limited Sun Exposure
Description: Limit sun exposure during peak hours of 10am-4pm

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dilute bleach baths
Description: Warm 10-15 minute dilute bleach baths every other day
Study: NCT02179853

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anakinra
Description: First two doses IV followed by SQ dosing
Study: NCT01397188

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PiCCO
Description: transpulmonary thermodilution technique

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: sham, no intervention
Description: no intervention
Study: NCT04280679

Intervention type: DEVICE
Group type: OTHER
Intervention: Sonovein 2
Description: Patient are treated with the HIFU device and the pysician is doing a compressive bandage
Study: NCT01249677

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin glargine
Description: 14 patients with type 2 diabetes on previous metformin therapy were treated with insulin glargine, aimed to normalize fasting glycaemia.
Study: NCT01180556

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotics
Description: Daily oral supplementation for four weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo administration
Study: NCT00738062

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Droxidopa
Description: 100 mg, oral, three times per day 200 mg, oral, three times per day 300 mg, oral, three times per day 400 mg, oral, three times per day 500 mg, oral, three times per day 600 mg, oral, three times per day
Study: NCT01997489

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzyme replacement
Description: Observational study of current treatment and with no comparative groups
Study: NCT00791297

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CDB-2914
Description: Contraceptive Vaginal Rings delivering a daily dose of 1500 or 2500 μg of CDB-2914

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CDB-2914
Description: Contraceptive Vaginal Rings delivering a daily dose of 1500 or 2500 μg of CDB-2914
Study: NCT03065205

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Propeller Health device + asthma navigator
Description: The patients will be monitored using the propeller health device for 6 months. The patients will be contacted at 2 month intervals by an asthma health educator to discuss barriers to adherence to asthma medications
Study: NCT00506922

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pentostatin
Description: Given intravenously on days +8, +15, +22 and +30 post transplant:~Group 2 - Pentostatin 0.5 mg/m\^2~Group 3 - Pentostatin 1 mg/m\^2~Group 4 - Pentostatin 1.5 mg/m\^2~Group 5 - Pentostatin 2 mg/m\^2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pentostatin
Description: Given intravenously on days +8, +15, +22 and +30 post transplant:~Group 2 - Pentostatin 0.5 mg/m\^2~Group 3 - Pentostatin 1 mg/m\^2~Group 4 - Pentostatin 1.5 mg/m\^2~Group 5 - Pentostatin 2 mg/m\^2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pentostatin
Description: Given intravenously on days +8, +15, +22 and +30 post transplant:~Group 2 - Pentostatin 0.5 mg/m\^2~Group 3 - Pentostatin 1 mg/m\^2~Group 4 - Pentostatin 1.5 mg/m\^2~Group 5 - Pentostatin 2 mg/m\^2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pentostatin
Description: Given intravenously on days +8, +15, +22 and +30 post transplant:~Group 2 - Pentostatin 0.5 mg/m\^2~Group 3 - Pentostatin 1 mg/m\^2~Group 4 - Pentostatin 1.5 mg/m\^2~Group 5 - Pentostatin 2 mg/m\^2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pentostatin
Description: Given intravenously on days +8, +15, +22 and +30 post transplant:~Group 2 - Pentostatin 0.5 mg/m\^2~Group 3 - Pentostatin 1 mg/m\^2~Group 4 - Pentostatin 1.5 mg/m\^2~Group 5 - Pentostatin 2 mg/m\^2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Given intravenously from day -2, and will be switched to oral dosing when tolerated.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Given intravenously from day -2, and will be switched to oral dosing when tolerated.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Given intravenously from day -2, and will be switched to oral dosing when tolerated.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Given intravenously from day -2, and will be switched to oral dosing when tolerated.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Given intravenously from day -2, and will be switched to oral dosing when tolerated.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Given intravenously on days +1, +3, and +6 at the dose of 5 mg/m2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Given intravenously on days +1, +3, and +6 at the dose of 5 mg/m2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Given intravenously on days +1, +3, and +6 at the dose of 5 mg/m2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Given intravenously on days +1, +3, and +6 at the dose of 5 mg/m2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Given intravenously on days +1, +3, and +6 at the dose of 5 mg/m2.
Study: NCT00192322

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CAIV-T 10^7
Description: a single intranasal 0.2 mL dose of liquid CAIV-T 107 (approximately 0.1 mL into each nostril)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CAIVT 10^5
Description: a single intranasal 0.2 mL dose of CAIV-T \<10\^5

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: a single intranasal 0.2 mL dose of placebo

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: TIV
Description: commercially available TIV injected intramuscularly
Study: NCT01860495

Intervention type: PROCEDURE
Intervention: perforated membrane
Description: perforated membrane that could give a chance for posetive contributionn of periosteal and gingival mesenchymal stem cells in periodontal regeneration

Intervention type: PROCEDURE
Intervention: G2
Description: tradetional occlusive collagen membrane
Study: NCT03590717

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: BCC-Only
Description: Households in the 'BCC-only' arm receive SBCC but do not receive vouchers.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Small-voucher
Description: Households in the 'Small-voucher' arm receive a voucher (\~$12-17) every month that entitles them to purchase fresh foods (fruits, vegetables and animal sourced foods). The households in this arm also receive the same social behavioural change communication (SBCC) messages as the 'BCC-only' arm.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Large-voucher
Description: Households in the 'Large-voucher' arm receive a larger voucher (\~$21-23) every month that entitles them to purchase fresh foods (fruits, vegetables and animal sourced foods). The households in this arm also receive the same social behavioural change communication (SBCC) messages as the 'BCC-only' arm.
Study: NCT02383238

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dapagliflozin
Description: 10 mg, oral for 6 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral for 6 weeks
Study: NCT04523298

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Non-ablative vaginal Erbium YAG laser treatment
Description: There are 3 visits where vaginal application of laser will be performed, with a 4-weeks interval. If needed, 3 extra laser applications can be added to the treatment (ie. with a maximum of 6 applications). Each application lasts around 15 minutes. The vaginal laser procedure will be performed in an outpatient setting, not requiring any specific preparation, analgesia or anesthesia, by one of two experienced operators.~Laser therapy is performed using a 2940 nm VEL (SP Spectro, Fotona, Slovenia(24)) with SMOOTH mode setting, which enables non-ablative, thermal-only operation(25). The parameters are selected based on extensive preclinical and clinical studies(26,27,28).~Each laser treatment session consists of a full vaginal canal irradiation (using a 360° circular adapter), followed by additional irradiation of the prolapsed anterior wall (using a 90° angular adaptor) and concluded with irradiation of the vestibule area.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pelvic floor exercises (PFE)
Description: Standard PFE in Belgium are 9 sessions with a pelvic floor physiotherapist of choice, which can be extended by another 9 sessions, if clinically indicated. There are different strategies, though that will be on discretion of the physiotherapist. We will register the type of physiotherapy (standard (PFMT) versus assisted pelvic floor muscles training (APFMT)), number of completed sessions and duration of therapy. What is exactly done by the patient is registered as a variable.
Study: NCT05588544

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Er,Cr:YSGG laser
Description: Use of laser at the degranulation step of the treatment

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Er,Cr:YSGG laser
Description: Use of laser at the degranulation step of the treatment
Study: NCT04244149

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Prolonged Exercise session
Description: After a standardized warm-up of 10 minutes of continuous running on a treadmill at 60% of their maximum heart rate (HRmax), subjects will perform a maximum oxygen consumption test (VO2max) with a gas analyzer (UltimaTM Series, MGC Diagnostic Corporation, St. Paul, MN, USA. The protocol will start with a slope of 1% at a speed of 10 km/h, with increments of 0.3 km/h every 30 s until volitional exhaustion. Finally, ten minutes after the treadmill test, volunteers will run 1 kilometer (t1km) as fast as possible and the time needed to cover the distance will be recorded.
Study: NCT00738062

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 100 mg, oral, three times per day 200 mg, oral, three times per day 300 mg, oral, three times per day 400 mg, oral, three times per day 500 mg, oral, three times per day 600 mg, oral, three times per day
Study: NCT01730547

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Autologous mesenchymal stem cells

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Autologous mesenchymal stem cells
Study: NCT01919346

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eculizumab

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Study: NCT04804059

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]-APX001 Oral Solution
Description: Total dose containing NMT 3.1 MBq (84.0 µCi) 14C

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]-APX001 Solution for Infusion
Description: Total dose containing NMT 3.4 MBq (93.0 µCi) 14C
Study: NCT03385798

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endowrist
Description: Anastomosis made by Endowrist

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endo-GIA
Description: Anastomosis made by Endo-GIA
Study: NCT02907450

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TwiCare®.
Study: NCT00873561

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NBI-6024
Description: 0.1, 0.5 or 1 mg NBI-6024 First 3 doses every 2 weeks. Remaining doses given monthly. Total duration of dosing 24 months. Placebo controlled.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NBI-6024
Description: 0.1, 0.5 or 1 mg NBI-6024 First 3 doses every 2 weeks. Remaining doses given monthly. Total duration of dosing 24 months. Placebo controlled.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NBI-6024
Description: 0.1, 0.5 or 1 mg NBI-6024 First 3 doses every 2 weeks. Remaining doses given monthly. Total duration of dosing 24 months. Placebo controlled.
Study: NCT03371121

Intervention type: OTHER
Group type: OTHER
Intervention: AT-AMIC (arthroscopic talus autologous matrix induced chondrogenesis)
Description: to fill arthroscopically osteochondral talar lesion
Study: NCT02222883

Intervention type: GENETIC
Intervention: Testing of BRCA status regarding germline and somatic mutation

Intervention type: GENETIC
Intervention: Testing of BRCA status regarding germline and somatic mutation
Study: NCT04143906

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinorelbine
Description: injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: injection
Study: NCT03894215

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGEN2034
Description: PD-1 antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGEN2034
Description: PD-1 antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGEN1884
Description: CTLA-4 antibody
Study: NCT03350308

Intervention type: OTHER
Intervention: hemodialysis
Description: The main objective is to establish a statistical predictive model of the risk of intradialytic hypotension during hemodialysis (HD) or hemodiafiltration (HDF) sessions based on the measurement of residual blood volume and excess extracellular hydration
Study: NCT03794934

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Structured Education for new glucose management devices
Description: Individualized professional education based on new glucose management devices in patients with type 1 diabetes mellitus

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Structured Education for new glucose management devices
Description: Individualized professional education based on new glucose management devices in patients with type 1 diabetes mellitus
Study: NCT03790449

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PreLiFe-programme
Description: The intervention group will receive a mobile preconception lifestyle programme (the PreLiFe-programme) in addition to standard care for 12 months or until an ongoing pregnancy is confirmed by ultrasound. The PreLiFe-programme includes a mobile application (PreLiFe-app) with the same treatment information as the attention control group in combination with a lifestyle programme. This new lifestyle programme includes tailored advice and skills training on diet and physical activity and mindfulness exercises. Additionally couples will be offered interaction with a health care provider through text messages and telephone interaction following the concept of blended care.
Study: NCT04143906

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: injection